|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
HK1220205A1
(zh)
|
2013-03-15 |
2017-04-28 |
Celgene Corporation |
修饰的t淋巴细胞
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
HRP20230265T1
(hr)
*
|
2014-08-22 |
2023-04-14 |
Celgene Corporation |
Postupci liječenja multiplog mijeloma imunomodulatornim spojevima u kombinaciji s protutijelima
|
|
JP6893873B2
(ja)
|
2014-12-01 |
2021-06-23 |
スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ |
新規の再生治療剤としてのｃａｍｋｋ１
|
|
WO2016118832A1
(en)
|
2015-01-22 |
2016-07-28 |
University Of Massachusetts |
Cancer immunotherapy
|
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
EP3484478B1
(en)
*
|
2016-07-15 |
2025-11-05 |
Viracta Subsidiary, Inc. |
Histone deacetylase inhibitors for use in immunotherapy
|
|
TWI843168B
(zh)
|
2016-10-11 |
2024-05-21 |
美商艾吉納斯公司 |
抗ｌａｇ－３抗體及其使用方法
|
|
EP3532638A4
(en)
*
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
TARGETING MICROARN-101-3 P IN CARCINOTHERAPY
|
|
MD3551660T2
(ro)
|
2016-12-07 |
2024-03-31 |
Agenus Inc |
Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
|
|
EP3551225A1
(en)
|
2016-12-07 |
2019-10-16 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
BR112019011450A2
(pt)
|
2016-12-09 |
2019-10-15 |
Onkimmune Ltd |
células naturais killer modificadas e uso das mesmas
|
|
WO2018121679A1
(zh)
*
|
2016-12-30 |
2018-07-05 |
四川大学 |
表达cxcr4的嵌合抗原受体修饰的淋巴细胞及制备方法和用途
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
RU2019128544A
(ru)
|
2017-03-27 |
2021-04-28 |
Нэшнл Юниверсити Оф Сингапур |
Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
|
|
CN117384929A
(zh)
|
2017-03-27 |
2024-01-12 |
新加坡国立大学 |
一种编码由细胞表达的嵌合受体的多核苷酸
|
|
WO2018177971A1
(en)
*
|
2017-03-27 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to obtain lymphoid progenitors
|
|
AU2018273963B2
(en)
*
|
2017-05-25 |
2023-07-20 |
University Of Central Florida Research Foundation, Inc. |
Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
|
|
TWI676483B
(zh)
*
|
2017-08-06 |
2019-11-11 |
強普生技股份有限公司 |
醫藥套組及其用途
|
|
US20200246393A1
(en)
*
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
IL273757B2
(en)
*
|
2017-10-02 |
2025-01-01 |
Gamida Cell Ltd |
Growing and using NK cell populations
|
|
US11760806B2
(en)
*
|
2017-11-03 |
2023-09-19 |
Sorrento Therapeutics, Inc. |
CD-38 directed chimeric antigen receptor constructs
|
|
KR20200098590A
(ko)
*
|
2017-12-12 |
2020-08-20 |
마크로제닉스, 인크. |
이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
|
|
CN108060137B
(zh)
*
|
2017-12-26 |
2021-07-02 |
博生吉医药科技(苏州)有限公司 |
Il7和il21修饰的nk92细胞、制备方法及其应用
|
|
WO2019127215A1
(en)
*
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
|
|
KR102338992B1
(ko)
|
2018-01-05 |
2021-12-14 |
지엔티 바이오테크 & 메디컬즈 코포레이션 |
종양 미세환경 및 면역요법의 조절을 위한 약제학적 조합물 및 방법
|
|
CN112055595B
(zh)
|
2018-01-22 |
2024-12-17 |
恩多塞特公司 |
Car t细胞的使用方法
|
|
US11814623B2
(en)
|
2018-01-30 |
2023-11-14 |
University Of Massachusetts |
Methods of treating a wound using epigenetic regulation
|
|
MY199514A
(en)
|
2018-02-01 |
2023-11-02 |
Nkmax Co Ltd |
Method of producing natural killer cells and composition for treating cancer
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
CN111918661A
(zh)
|
2018-02-21 |
2020-11-10 |
得克萨斯大学体系董事会 |
用于活化和扩增自然杀伤细胞的方法及其用途
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
EP3768281B1
(en)
*
|
2018-03-19 |
2023-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for t-cell and cytokine activation
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
JP2021521193A
(ja)
|
2018-04-18 |
2021-08-26 |
スンマ ヘルスＳｕｍｍａ Ｈｅａｌｔｈ |
虚血および心筋症の処置のための組成物および方法
|
|
WO2019200586A1
(en)
*
|
2018-04-19 |
2019-10-24 |
The Chinese University Of Hong Kong |
Modified nk cells and uses thereof
|
|
GB201807050D0
(en)
*
|
2018-04-30 |
2018-06-13 |
Cellprotect Nordic Pharmaceuticals Ab |
Medical uses
|
|
KR102373502B1
(ko)
|
2018-05-14 |
2022-03-11 |
주식회사 금호에이치티 |
골수유래억제세포 관련 질환의 예방 및 치료 용도
|
|
KR102069704B1
(ko)
*
|
2018-05-16 |
2020-01-23 |
고려대학교 산학협력단 |
Hdac 억제제를 이용한 사람 유래 자연살해세포의 확장 배양법
|
|
US12304962B2
(en)
*
|
2018-05-30 |
2025-05-20 |
Glycostem Therapeutics B.V. |
CAR NK cells
|
|
WO2019240934A1
(en)
|
2018-06-12 |
2019-12-19 |
Promab Biotechnologies, Inc. |
Plap-car-effector cells
|
|
CN108815186A
(zh)
*
|
2018-06-14 |
2018-11-16 |
上海鸣大生物科技有限公司 |
一种治疗hpv持续感染引起疾病的药物及制备方法与应用
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
EP3846829A4
(en)
*
|
2018-09-05 |
2022-09-14 |
Arizona Board of Regents on behalf of Arizona State University |
ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
|
|
CA3114707A1
(en)
*
|
2018-10-19 |
2020-04-23 |
Regents Of The University Of Minnesota |
Nk engager molecules and methods of use thereof
|
|
SG11202104524YA
(en)
|
2018-11-01 |
2021-05-28 |
Gracell Biotechnologies Shanghai Co Ltd |
Compositions and methods for t cell engineering
|
|
KR20210111244A
(ko)
*
|
2018-11-30 |
2021-09-10 |
셀룰래리티 인코포레이티드 |
태반-유래 동종이계 car-t 세포 및 이의 용도
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
CA3133419A1
(en)
*
|
2019-03-21 |
2020-09-24 |
Gamida Cell Ltd. |
Expansion and use of expanded nk cell fractions suitable for transplantation in combination therapy
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
US20220273716A1
(en)
*
|
2019-07-25 |
2022-09-01 |
Celularity Inc. |
Populations of natural killer cells comprising a cd38 chimeric antigen receptor
|
|
US20220340927A1
(en)
*
|
2019-09-01 |
2022-10-27 |
Exuma Biotech Corp. |
Methods and compositions for the modification and delivery of lymphocytes
|
|
EP4041256A4
(en)
*
|
2019-10-10 |
2023-11-08 |
Arizona Board of Regents on behalf of Arizona State University |
Oncolytic viruses that express multi-specific immune cell engagers
|
|
US20230017590A1
(en)
*
|
2019-11-27 |
2023-01-19 |
Deverra Therapeutics Inc. |
Compositions and methods for culturing hematopoietic stem and progenitor cells
|
|
CN115943214A
(zh)
*
|
2019-11-28 |
2023-04-07 |
格雷克斯迪姆医疗私人有限公司 |
用于获得car-nk细胞的方法
|
|
EP4114400A4
(en)
*
|
2020-03-05 |
2023-10-18 |
Exuma Biotech Corp. |
Methods and compositions for the delivery of modified lymphocyte aggregates
|
|
WO2021188836A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Barron Annelise E |
Upregulation of cathelicidin gene expression as an adjuvant to other treatments for diseases
|
|
CN116249770A
(zh)
*
|
2020-09-22 |
2023-06-09 |
环球生物科技再生医疗集团有限公司 |
表达car的自然杀伤细胞与双特异性抗原结合分子作为癌症治疗剂的方法和组合物
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN113398264B
(zh)
*
|
2021-08-06 |
2022-04-29 |
朱有建 |
Nk细胞及其组合物在治疗癌症中的用途
|
|
KR20240054424A
(ko)
*
|
2021-08-10 |
2024-04-25 |
가미다-셀 리미티드 |
항-her2 car nk 세포, 이의 생산 방법 및 용도
|
|
CN113577267B
(zh)
*
|
2021-09-06 |
2022-04-08 |
江西北正干细胞生物科技有限公司 |
Nk细胞和抗体的药物组合物及其在治疗癌症中的用途
|
|
AU2022342919A1
(en)
*
|
2021-09-08 |
2024-03-14 |
Gaia Biomedicine Inc. |
Method for treating cells
|
|
EP4180049A1
(en)
*
|
2021-11-16 |
2023-05-17 |
Ostravska univerzita |
Therapeutic composition for cancer treatment
|
|
CN114058584B
(zh)
*
|
2022-01-07 |
2022-07-01 |
山东省齐鲁干细胞工程有限公司 |
一种临床用自然杀伤细胞的制备方法
|
|
CN115927169B
(zh)
*
|
2022-10-11 |
2023-08-11 |
再造再生医学科技(杭州)有限公司 |
用于扩增cd34+造血干细胞的培养液和体外扩增cd34+造血干细胞的方法
|
|
CN119082021B
(zh)
*
|
2024-09-30 |
2025-03-28 |
广东壹加再生医学研究院有限公司 |
一种增强型nk细胞及其制备方法
|